Research Article

Department of General Surgery, Xiangya Hospital Central South University, Changsha, 410000, China

‡Authors contributed equally to this work

Search for more papers by this author

Qing He‡

https://orcid.org/0009-0009-4457-6013

GeneTalks Biotech Co., Ltd, Changsha, Hunan, 410000, PR China

‡Authors contributed equally to this work

Search for more papers by this author

Qin Cao

Department of Gastroenterology, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, 310016, China

Search for more papers by this author

Jun Chuan

GeneTalks Biotech Co., Ltd, Changsha, Hunan, 410000, PR China

Search for more papers by this author

Ang Qin

Department of Endoscope Center, The Affiliated Cancer Hospital of Xiangya School of Medicine, Hunan Cancer Hospital, Central South University, Changsha, Hunan, 410013, China

Search for more papers by this author

Lin Tang

GeneTalks Biotech Co., Ltd, Changsha, Hunan, 410000, PR China

Search for more papers by this author

Xinyue Zhang

Department of Neurology, Xiangya Hospital, Central South University, Changsha, 410000, China

Search for more papers by this author

Changhe Xiao

GeneTalks Biotech Co., Ltd, Changsha, Hunan, 410000, PR China

Search for more papers by this author

Biyin Zhu

GeneTalks Biotech Co., Ltd, Changsha, Hunan, 410000, PR China

Search for more papers by this author

Meiling Hu

GeneTalks Biotech Co., Ltd, Changsha, Hunan, 410000, PR China

Search for more papers by this author

Lei Chang

GeneTalks Biotech Co., Ltd, Changsha, Hunan, 410000, PR China

Search for more papers by this author

Zhong xin Bu

GeneTalks Biotech Co., Ltd, Changsha, Hunan, 410000, PR China

Search for more papers by this author

Lanqi Fu

GeneTalks Biotech Co., Ltd, Changsha, Hunan, 410000, PR China

Search for more papers by this author

Ting Yang

GeneTalks Biotech Co., Ltd, Changsha, Hunan, 410000, PR China

Search for more papers by this author

Yu Wang

*Author for correspondence:

E-mail Address: yu_wang@tongji.edu.cn

https://orcid.org/0000-0002-1000-182X

GeneTalks Biotech Co., Ltd, Changsha, Hunan, 410000, PR China

School of Life Sciences & Technology, Tongji University, Shanghai, 200092, China

Search for more papers by this author

Weidong Liu

**Author for correspondence:

E-mail Address: weidong.liu@csu.edu.cn

Department of General Surgery, Xiangya Hospital Central South University, Changsha, 410000, China

Search for more papers by this author

Published Online:16 Jan 2024https://doi.org/10.2217/epi-2023-0290

View article

Abstract

Purpose: The performance and clinical accuracy of combined SDC2/NDRG4 methylation were evaluated in diagnosing colorectal cancer (CRC) and advanced adenoma. Methods: A total of 2333 participants were enrolled to assess the sensitivity and specificity of biomarkers in diagnosing CRC in a multicenter clinical trial through feces DNA methylation tests. Results:SDC2/NDRG4 methylation showed excellent performance for CRC detection in biomarker research and the real world. Its sensitivity for detecting CRC, early CRC and advanced adenoma were 92.06%, 91.45% and 62.61%, respectively. Its specificity was 94.29%, with a total coincidence rate of 88.28%. When interference samples were included, the specificity was still good (82.61%). Therefore, the SDC2/NDRG4 methylation test showed excellent performance in detecting CRC and advanced adenoma under clinical application.

Plain language summary

Colorectal cancer (CRC) is one of the most malignant tumors of the digestive system and second only to breast cancer and lung cancer in terms of global incidence. Early CRCs are challenging to determine given their atypical nature. In contrast, late CRC symptoms are affected by the type, location and range of the lesion and complications. Therefore, CRC patients are generally diagnosed late, present with a high degree of malignancy, and have poor prognosis and 5-year survival rates. The current study therefore evaluated whether SDC2 and NDRG4 methylation could be used for diagnosis CRCs at an early stage and whether it has the potential to detect asymptomatic patients with adenomas. The findings presented herein will certainly help support the early diagnosis of CRC and precancerous lesions in clinical practice.

Tweetable abstract

SDC2/NDRG4 methylation showed excellent performance for CRC detection in a real-world setting. Its sensitivity for detecting CRC, early CRC and advanced adenoma were 92.06%, 91.45% and 62.61%, respectively. Its specificity was 94.29%, with a total coincidence rate of 88.28%.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet 394(10207), 1467–1480 (2019).
MedlineGoogle Scholar
2. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021). •• Provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Colorectal cancer (CRC) is also the second leading cause of cancer-related deaths worldwide, with an estimated 1.93 million new cases having been diagnosed in 2020.
MedlineGoogle Scholar
3. Yin Z, Yao C, Zhang L, Qi S. Application of artificial intelligence in diagnosis and treatment of colorectal cancer: a novel prospect. Front. Med. (Lausanne) 10, 1128084 (2023).
MedlineGoogle Scholar
4. Nfonsam V, Wusterbarth E, Gong A, Vij P. Early-onset colorectal cancer. Surg. Oncol. Clin. N. Am. 31(2), 143–155 (2022).
MedlineGoogle Scholar
5. Simon K. Colorectal cancer development and advances in screening. Clin. Interv. Aging 11, 967–976 (2016).
Medline CASGoogle Scholar
6. Muller D, Gyorffy B. DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer. Biochim. Biophys. Acta Rev. Cancer 1877(3), 188722 (2022).
Medline CASGoogle Scholar
7. Eng C, Jacome AA, Agarwal R et al. A comprehensive framework for early-onset colorectal cancer research. Lancet Oncol. 23(3), e116–e128 (2022).
MedlineGoogle Scholar
8. Anghel SA, Ionita-Mindrican CB, Luca I, Pop AL. Promising epigenetic biomarkers for the early detection of colorectal cancer: a systematic review. Cancers (Basel) 13(19), (2021).
MedlineGoogle Scholar
9. Chen J, Sun H, Tang W et al. DNA methylation biomarkers in stool for early screening of colorectal cancer. J. Cancer 10(21), 5264–5271 (2019).
Medline CASGoogle Scholar
10. Ruiz XD, Mlakar LR, Yamaguchi Y et al. Syndecan-2 is a novel target of insulin-like growth factor binding protein-3 and is over-expressed in fibrosis. PLOS ONE 7(8), e43049 (2012).
Medline CASGoogle Scholar
11. Lee H, Kim Y, Choi Y, Choi S, Hong E, Oh ES. Syndecan-2 cytoplasmic domain regulates colon cancer cell migration via interaction with syntenin-1. Biochem. Biophys. Res. Commun. 409(1), 148–153 (2011).
Medline CASGoogle Scholar
12. Han I, Park H, Oh ES. New insights into syndecan-2 expression and tumourigenic activity in colon carcinoma cells. J. Mol. Histol. 35(3), 319–326 (2004).
Medline CASGoogle Scholar
13. de Klaver W, Wisse PHA, van Wifferen F et al. Clinical validation of a multitarget fecal immunochemical test for colorectal cancer screening: a diagnostic test accuracy study. Ann. Intern. Med. 174(9), 1224–1231 (2021).
MedlineGoogle Scholar
14. Han YD, Oh TJ, Chung TH et al. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA. Clin. Epigenetics 11(1), 51 (2019). •• The results of this study validated the capability of stool DNA-based-SDC2 methylation tests by LTE-qMSP for early detection of CRC patients with high specificity. Stool DNA-based meSDC2 LTE-qMSP showed an overall sensitivity of 90.2% with AUC of 0.902 in detecting CRC (0–IV) not associated with tumor stage, location, sex or age (p > 0.05), with a specificity of 90.2%.
Medline CASGoogle Scholar
15. Zhang W, Yang C, Wang S et al. SDC2 and TFPI2 methylation in stool samples as an integrated biomarker for early detection of colorectal cancer. Cancer Manag. Res. 13, 3601–3617 (2021).
Medline CASGoogle Scholar
16. Oh TJ, Oh HI, Seo YY et al. Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer. Clin. Epigenetics 9, 126 (2017). •• Taken together, the manuscript result indicates that a stool DNA-based SDC2 methylation test by LTE-qMSP is a potentially noninvasive diagnostic tool for the early detection of CRC. The overall sensitivity was 90.0% for detecting CRC and 33.3% for detecting small polyps, with a specificity of 90.9%.
MedlineGoogle Scholar
17. Zhou RH, Kokame K, Tsukamoto Y, Yutani C, Kato H, Miyata T. Characterization of the human NDRG gene family: a newly identified member, NDRG4, is specifically expressed in brain and heart. Genomics 73(1), 86–97 (2001).
Medline CASGoogle Scholar
18. Qu X, Jia H, Garrity DM et al. Ndrg4 is required for normal myocyte proliferation during early cardiac development in zebrafish. Dev. Biol. 317(2), 486–496 (2008).
Medline CASGoogle Scholar
19. Melotte V, Lentjes MH, van den Bosch SM et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J. Natl Cancer Inst. 101(13), 916–927 (2009).
Medline CASGoogle Scholar
20. Chu D, Zhang Z, Zhou Y et al. NDRG4, a novel candidate tumor suppressor, is a predictor of overall survival of colorectal cancer patients. Oncotarget 6(10), 7584–7596 (2015).
MedlineGoogle Scholar
21. Zeng H, Chen K, Ma C et al. High-throughput primer design by scoring in piecewise logistic model for multiple polymerase chain reaction variants. Sci. Rep. 12(1), 21136 (2022).
Medline CASGoogle Scholar
22. Casey Y, Demb J, Enwerem N et al. Risk of incident and fatal colorectal cancer after young-onset adenoma diagnosis: a national cohort study. Am. J. Gastroenterol. doi: 10.14309/ajg.0000000000002296 (2023).
MedlineGoogle Scholar
23. Wu Z, Li Y, Zhang Y et al. Colorectal cancer screening methods and molecular markers for early detection. Technol. Cancer Res. Treat. 19, 1533033820980426 (2020). •• Illustrates novel routine screening and diagnostic methods (e.g., endoscopy and CT colonoscopy, SEPT9 methylation assay, fecal test) and found reliable molecular markers for the early diagnosis of CRC.
Google Scholar
24. Saraiva MR, Rosa I, Claro I. Early-onset colorectal cancer: A review of current knowledge. World J. Gastroenterol. 29(8), 1289–1303 (2023).
Medline CASGoogle Scholar
25. Collaborative R, Zaborowski AM, Abdile A et al. Characteristics of early-onset vs late-onset colorectal cancer: a review. JAMA Surg. 156(9), 865–874 (2021).
MedlineGoogle Scholar
26. Colorectal Cancer Screening (PDQ(R)): Health Professional Version. In: PDQ Cancer Information Summaries. MD, USA (2002).
Google Scholar
27. Hanna M, Dey N, Grady WM. Emerging tests for noninvasive colorectal cancer screening. Clin. Gastroenterol. Hepatol. 21(3), 604–616 (2023). • Reviewed current screening modalities and discussed the principles behind the most promising emerging CRC screening tests and the data supporting their potential to be used in clinical practice.
MedlineGoogle Scholar
28. Bresalier RS. Colorectal cancer screening in a changing world. Gastroenterol. Clin. North Am. 51(3), 577–591 (2022).
MedlineGoogle Scholar
29. Jin X, Cai C, Zhao J et al. Opportunistic colonoscopy in healthy individuals: a non-trivial risk of adenoma. PLOS ONE 18(4), e0283575 (2023).
Medline CASGoogle Scholar
30. Luk GD, Desai TK, Conteas CN, Moshier JA, Silverman AL. Biochemical markers in colorectal cancer: diagnostic and therapeutic implications. Gastroenterol. Clin. North Am. 17(4), 931–940 (1988).
Medline CASGoogle Scholar
31. Kijima S, Sasaki T, Nagata K, Utano K, Lefor AT, Sugimoto H. Preoperative evaluation of colorectal cancer using CT colonography, MRI, and PET/CT. World J. Gastroenterol. 20(45), 16964–16975 (2014).
MedlineGoogle Scholar
32. Pickhardt PJ, Choi JR, Hwang I et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N. Engl. J. Med. 349(23), 2191–2200 (2003).
Medline CASGoogle Scholar
33. Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 371(2), 187–188 (2014).
Medline CASGoogle Scholar
34. Robertson DJ, Imperiale TF. Stool testing for colorectal cancer screening. Gastroenterology 149(5), 1286–1293 (2015).
MedlineGoogle Scholar
35. Ding Q, Kong X, Zhong W, Liu W. Fecal biomarkers: Non-invasive diagnosis of colorectal cancer. Front. Oncol. 12, 971930 (2022).
Medline CASGoogle Scholar
36. Kamel F, Eltarhoni K, Nisar P, Soloviev M. Colorectal cancer diagnosis: the obstacles we face in determining a non-invasive test and current advances in biomarker detection. Cancers (Basel) 14(8), (2022).
Google Scholar
37. Imperiale TF, Ransohoff DF, Itzkowitz SH et al. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med. 370(14), 1287–1297 (2014).
Medline CASGoogle Scholar
38. Lu H, Huang S, Zhang X et al. DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA. Oncol. Lett. 8(4), 1751–1756 (2014). • Showed that methylation of the SFRP2, GATA4/5, NDRG4 and VIM promoters in fecal DNA is associated with the presence of colorectal tumors. Therefore, the detection of aberrantly methylated DNA in fecal samples may present a promising, noninvasive screening method for CRC.
Medline CASGoogle Scholar
39. Ahlquist DA, Zou H, Domanico M et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 142(2), 248–256; quiz e225-246 (2012).
Medline CASGoogle Scholar
40. Wang J, Liu S, Wang H et al. Robust performance of a novel stool DNA test of methylated SDC2 for colorectal cancer detection: a multicenter clinical study. Clin. Epigenetics 12(1), 162 (2020). • Describes a noninvasive sDNA test using methylated SDC2 as the exclusive biomarker is a clinically viable and accurate CRC detection method.
Medline CASGoogle Scholar
41. Wang Z, Shang J, Zhang G et al. Evaluating the clinical performance of a dual-target stool DNA test for colorectal cancer detection. J. Mol. Diagn. 24(2), 131–143 (2022). • The iColocomf test showed robust performance for the early detection of colorectal cancer and potential monitoring ability in clinical practice.
Medline CASGoogle Scholar
42. Hibi K, Goto T, Shirahata A et al. Detection of TFPI2 methylation in the serum of gastric cancer patients. Anticancer Res. 31(11), 3835–3838 (2011).
Medline CASGoogle Scholar
43. Ma L, Gong J, Zhao M et al. A novel stool methylation test for the non-invasive screening of gastric and colorectal cancer. Front. Oncol. 12, 860701 (2022).
Medline CASGoogle Scholar
44. Bartak BK, Fodor T, Kalmar A et al. A liquid biopsy-based approach for monitoring treatment response in post-operative colorectal cancer patients. Int. J. Mol. Sci. 23(7), 3774 (2022).
Medline CASGoogle Scholar
45. Jin S, Zhu D, Shao F et al. Efficient detection and post-surgical monitoring of colon cancer with a multi-marker DNA methylation liquid biopsy. Proc. Natl Acad. Sci. USA 118(5), e2017421118 (2021).
Medline CASGoogle Scholar

Vol. 16, No. 2

Supplemental Materials

Metrics

Downloaded 108 times

History

Received 15 August 2023

Accepted 15 December 2023

Published online 16 January 2024

Published in print January 2024

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/epi-2023-0290

Author contributions

All authors contributed to the study conception and design. Z Ke, Q He, X Zhang, B Zhu, M Hu, L Chang and ZX BU performed experiments; Q Cao, A Qin, C Xiao and L Fu collected data (patient information and stool sample preparation); Z Ke, Q He, Q Cao, J Chuan, A Qin, L Tang and T Yang analyzed the data; Y Wang and W Liu designed the experiment. Z Ke, Q He, L Tang, Y Wang and W Liu take part in writing, reviewing and revising article. Y Wang and W Liu are the guarantors of this work and, as such, had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

Financial disclosure

This work was supported by Project of the Natural Science Foundation of Hunan Province (grant no. 2021JJ40512). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

GeneTalks Biotech Co., Ltd and department of general surgery, Xiangya Hospital Central South University were jointly presiding the project in scientific research. All participating units declare that they have no commercial interests with each other. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

Ethical conduct of research

All methods were carried out in accordance with relevant guidelines and regulations. Biomarker research approval was provided by the medical ethics committee of Xiangya Hospital of Central South University (reference no: 201712844). For the clinical study, a double-blind study involving three hospitals (Xiangya Hospital, Central South University, Hunan Cancer Hospital and Sir Run Run Shaw Hospital, Zhejiang University) was designed, which enrolled over 1000 participants according to the Technical Guidelines for Clinical Trials of in Vitro Diagnostic Reagents released in 2021 by the NMPA (reference no: GCP [2021010005], 2021-259, 20210420-8). Informed consent was obtained from all individual participants included in the study.

Writing assistance

The authors received English language editing services from ENAGO by Project (grant no. 2021JJ40512) .

Data sharing statement

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. The authors certify that this manuscript reports original clinical trial data. Deidentified, individual data that underlie the results reported in this article (text, tables, figures and appendices), along with the study protocol and statistical analysis plan, will be available will be available indefinitely for anyone who wants access to them. After 24 months following article publication, the data will be available in ResMan (http://www.medresman.org.cn/login.aspx).

PDF download

Evaluating the clinical performance of SDC2/NDRG4 methylation for colorectal cancer detection

Abstract

Plain language summary

Tweetable abstract

References